<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001907'>Thromboembolic disease</z:hpo> (TED) has been recognized as a complication of <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) since the 1930s (Bargen &amp; Barker 1936) </plain></SENT>
<SENT sid="1" pm="."><plain>The relative contributions of inherited or acquired <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> and the <z:mp ids='MP_0001845'>inflammatory response</z:mp> to the mechanism of this tendency is unclear </plain></SENT>
<SENT sid="2" pm="."><plain>Thrombotic events are more common in active disease although significant numbers also occur spontaneously, when the disease is in clinical remission (Talbot et al </plain></SENT>
<SENT sid="3" pm="."><plain>1986; Jackson et al </plain></SENT>
<SENT sid="4" pm="."><plain>1997) </plain></SENT>
<SENT sid="5" pm="."><plain>Studies looking at the prevalence of specific thrombophilic states such as <z:hpo ids='HP_0001976'>Antithrombin III deficiency</z:hpo> (Jackson et al </plain></SENT>
<SENT sid="6" pm="."><plain>1997; Lake, Stauffer &amp; Stuart 1978; Cianco et al </plain></SENT>
<SENT sid="7" pm="."><plain>1996; Ghosh et al </plain></SENT>
<SENT sid="8" pm="."><plain>1983), <z:e sem="disease" ids="C0584960" disease_type="Disease or Syndrome" abbrv="">Factor V Leiden mutation</z:e> (APC Resistance) (Jackson et al </plain></SENT>
<SENT sid="9" pm="."><plain>1997; Probert et al </plain></SENT>
<SENT sid="10" pm="."><plain>1997; Ardizzone et al </plain></SENT>
<SENT sid="11" pm="."><plain>1998; Liebman et al </plain></SENT>
<SENT sid="12" pm="."><plain>1998), anticardiolipin antibodies (Ciancio et al </plain></SENT>
<SENT sid="13" pm="."><plain>1996), Protein C (Wyshock, Caldwell &amp; Crowley 1988; Korsten &amp; Reis 1992) and <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">Protein S deficiencies</z:e> (Jorens et al </plain></SENT>
<SENT sid="14" pm="."><plain>1990; Aadland et al </plain></SENT>
<SENT sid="15" pm="."><plain>1992) in IBD have been contradictory or equivocal </plain></SENT>
<SENT sid="16" pm="."><plain>We had previously found that IBD patients with a history of TED are not more likely to have a laboratory thrombophilic abnormality than those with uncomplicated disease </plain></SENT>
<SENT sid="17" pm="."><plain>We also demonstrated that the prevalence of heterogenous laboratory thrombophilic abnormalities (usually minor) in <z:hpo ids='HP_0000001'>all</z:hpo> IBD patients may be as high as 60%, much higher than the recognized prevalence of TED (Lim, Jones &amp; Gould 1996) </plain></SENT>
<SENT sid="18" pm="."><plain>We wondered how this would compare with the healthy non-IBD population </plain></SENT>
<SENT sid="19" pm="."><plain>We have therefore explored the prevalence of such thrombophilic abnormalities in a group of IBD patients who had no history of TED and compared them with healthy age and sex matched controls </plain></SENT>
</text></document>